Real-world effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection among adolescents (12 to 17-year-olds) in Malaysia

被引：15

作者：

Husin, Masliyana ^{[1
]}

Tok, Peter Seah Keng ^{[1
]}

Suah, Jing Lian ^{[1
]}

Thevananthan, Thevesh ^{[2
]}

Tng, Boon Hwa ^{[1
]}

Peariasamy, Kalaiarasu M. ^{[1
]}

Sivasampu, Sheamini ^{[1
]}

机构：

[1] Minist Hlth Malaysia, Natl Inst Hlth, Inst Clin Res, 1 Jalan Setia Murni U13-52,Seksyen U13, Shah Alam 40170, Selangor, Malaysia

[2] Minist Hlth Malaysia, Dis Control Div, Putrajaya 62590, Malaysia

来源：

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | 2022年 / 121卷

关键词：

COVID-19; Vaccines; SARS-CoV-2; BNT162b2; Effectiveness; Adolescent; Malaysia;

D O I：

10.1016/j.ijid.2022.04.053

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Objectives: In this study, we aimed to investigate vaccine effectiveness (VE) against SARS-CoV-2 infections among adolescents aged 12 to 17 years in Malaysia and examine potential VE differences after full vaccination. Methods: We consolidated data on COVID-19 testing, vaccination, and outcomes for all public schoolgoing adolescents in Malaysia from September 1, 2021, to December 31, 2021, and estimated the VE against SARS-CoV-2 infections during this period. Cases were defined as positive tests, either by reverse transcriptase- PCR (RT-PCR) or rapid antigen (RTK-Ag) testing, while controls were negative tests. Secondarily, we restricted the analysis to all tests performed in December 2021 and compared VE by month of full vaccination. Results: A total of 175,880 eligible tests (53.4% or 93,995 RT-PCR tests) were included. After full vaccination with BNT162b2, VE against SARS-CoV-2 infections was 65.7% (95% confidence interval [CI] 64.4, 66.9) over the study period. When restricted to tests in December 2021, VEs for those fully vaccinated in September 2021, October 2021, and November 2021 were comparable (60.6% [95% CI 23.7, 81.5], 56.9% [95% CI 51.1, 62.0], and 65.7% [95% CI 59.8, 70.7] respectively). Conclusions: Among adolescents, full vaccination with BNT162b2 offered considerable protection against SARS-CoV-2 infections over at least three months without substantial evidence of waning. (C) 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

引用

页码：55 / 57

页数：3

共 10 条

[1]

[Anonymous], 2021, Strategy to achieve global Covid-19 vaccination by mid -2022

[2]

Chiew CJ, PREPRINT, DOI [10.2139/ssrn.3996796, DOI 10.2139/SSRN.3996796]

[3]

Dorabawila V., 2022, PREPRINT, DOI [DOI 10.1101/2022.02.25.22271454V1, DOI 10.1101/2022.02.25.22271454]

[4] Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents [J].

Frenck, Robert W., Jr. ;

Klein, Nicola P. ;

Kitchin, Nicholas ;

Gurtman, Alejandra ;

Absalon, Judith ;

Lockhart, Stephen ;

Perez, John L. ;

Walter, Emmanuel B. ;

Senders, Shelly ;

Bailey, Ruth ;

Swanson, Kena A. ;

Ma, Hua ;

Xu, Xia ;

Koury, Kenneth ;

Kalina, Warren V. ;

Cooper, David ;

Jennings, Timothy ;

Brandon, Donald M. ;

Thomas, Stephen J. ;

Tureci, Ozlem ;

Tresnan, Dina B. ;

Mather, Susan ;

Dormitzer, Philip R. ;

Sahin, Ugur ;

Jansen, Kathrin U. ;

Gruber, William C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (03) :239-250

[5]

Klein NP, 2022, MMWR-MORBID MORTAL W, V71, P352, DOI 10.15585/mmwr.mm7109e3

[6] Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents [J].

Olson, S. M. ;

Newhams, M. M. ;

Halasa, N. B. ;

Price, A. M. ;

Boom, J. A. ;

Sahni, L. C. ;

Pannaraj, P. S. ;

Irby, K. ;

Walker, T. C. ;

Schwartz, S. P. ;

Maddux, A. B. ;

Mack, E. H. ;

Bradford, T. T. ;

Schuster, J. E. ;

Nofziger, R. A. ;

Cameron, M. A. ;

Chiotos, K. ;

Cullimore, M. L. ;

Gertz, S. J. ;

Levy, E. R. ;

Kong, M. ;

Cvijanovich, N. Z. ;

Staat, M. A. ;

Kamidani, S. ;

Chatani, B. M. ;

Bhumbra, S. S. ;

Bline, K. E. ;

Gaspers, M. G. ;

Hobbs, C., V ;

Heidemann, S. M. ;

Maamari, M. ;

Flori, H. R. ;

Hume, J. R. ;

Zinter, M. S. ;

Michelson, K. N. ;

Zambrano, L. D. ;

Campbell, A. P. ;

Patel, M. M. ;

Randolph, G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (08) :713-723

[7]

Prunas O, 2022, medRxiv, DOI [10.1101/2022.01.04.22268776, 10.1101/2022.01.04.22268776, DOI 10.1101/2022.01.04.22268776]

[8] Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents [J].

Reis, Ben Y. ;

Barda, Noam ;

Leshchinsky, Michael ;

Kepten, Eldad ;

Hernan, Miguel A. ;

Lipsitch, Marc ;

Dagan, Noa ;

Balicer, Ran D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (22) :2101-2103

[9] Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study [J].

Suah, Jing Lian ;

Husin, Masliyana ;

Tok, Peter Seah Keng ;

Tng, Boon Hwa ;

Thevananthan, Thevesh ;

Low, Ee Vien ;

Appannan, Maheshwara Rao ;

Zin, Faizah Muhamad ;

Zin, Shahanizan Mohd ;

Yahaya, Hazlina ;

Peariasamy, Kalaiarasu M. ;

Sivasampu, Sheamini .

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 119 :69-76

[10] PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio [J].

Suah, Jing Lian ;

Tok, Peter Seah Keng ;

Ong, Su Miin ;

Husin, Masliyana ;

Tng, Boon Hwa ;

Sivasampu, Sheamini ;

Thevananthan, Thevesh ;

Appannan, Maheshwara Rao ;

Muhamad Zin, Faizah ;

Mohd Zin, Shahanizan ;

Yahaya, Hazlina ;

Rusli, Norhayati ;

Ujang, Mohd Fikri ;

Mohd Ibrahim, Hishamshah ;

Abdullah, Noor Hisham ;

Peariasamy, Kalaiarasu M. .

VACCINES, 2021, 9 (12)

← 1 →